Clinical trials: Nervous System Disorder
Stroke
PROPEL Randomized Trial
It is important for people with stroke to exercise in order to improve their overall recovery and general health. However, these individuals are less physically active than people without stroke, and they often do not achieve the…
- Trial name
- NCT02951338
- Testing
- PROPEL program, Group aerobic exercise
- Where
- 5 sites in Canada
- Volunteers
- 57 people
- Sponsor
- Toronto Rehabilitation Institute
Epilepsy
Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites
The purpose of this study is to determine the effects of age on the pharmacokinetic profile of BIA 2-093 and its active metabolites.
- Trial name
- NCT02172755
- Testing
- BIA 2-093
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Traumatic Brain Injury
Brain Injury Rehabilitation Improving the Transition Experience
Each year, about 2.8 million people sustain a traumatic brain injury (TBI) in the United States, and at least 25 percent of these injuries are classified as moderate to severe.
- Trial name
- BRITE (NCT03422276)
- Testing
- Rehabilitation Discharge Plan, Rehabilitation Transition Plan
- Where
- 6 sites in United States
- Volunteers
- 1,555 people
- Sponsor
- University of Washington
Arterial Stiffness, Renin Angiotensin Aldosterone System
RAAS and Arterial Stiffness in SCI
The study is examining differences in central arterial stiffness, orthostatic changes in blood pressure, norepinephrine, and plasma renin in individuals with spinal cord injury compared with age-matched uninjured controls.
- Conditions
- Arterial Stiffness, Renin Angiotensin Aldosterone System, Orthostatic Hypotension, Spinal Cord Injury
- Trial name
- NCT04510974
- Testing
- Spinal Cord Injury
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- James J. Peters Veterans Affairs Medical Center
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
This trial was a multi-center, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of AXS-05 compared to placebo for the treatment of agitation associated with Alzheimer's disease.
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation
- Trial name
- ADVANCE-2 (NCT05557409)
- Testing
- AXS-05
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 408 people
- Sponsor
- Axsome Therapeutics, Inc.
Cerebral Palsy, Physical Activity
Effects of Hippotherapy on Physical Fitness and Attention in Cerebral Palsy
This research analyzes whether hippotherapy improves the physical activity, cardiopulmonary fitness, and attention in children with cerebral palsy and whether this enhances their general health and quality of life.
- Conditions
- Cerebral Palsy, Physical Activity, Attention Disorder
- Trial name
- NCT03870893
- Testing
- hippotherapy
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Samsung Medical Center
Traumatic Brain Injury
ACTIVE: Activity Therapy to Increase Veteran Engagement
Depression is common after traumatic brain injury (TBI) and may have wide-ranging consequences. Post-TBI depression may impede reintegration into the family and community and lead to lower quality of life and heightened suicide…
- Trial name
- ACTIVE (NCT04976621)
- Testing
- Behavioral Activation, Treatment as Usual
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- VA Office of Research and Development
Primary Insomnia
Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)
This is a multicenter study to test the hypothesis that suvorexant (MK-4305) is superior to placebo in improving insomnia as measured by change from baseline in: subjective total sleep time and time to sleep onset, wake time…
- Trial name
- NCT01097616
- Testing
- Suvorexant High Dose (HD), Suvorexant Low Dose (LD)
- Volunteers
- 1,023 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypoxic-Ischemic Encephalopathy
Holding, Stress, and Bonding During Therapeutic Hypothermia
Ten infants undergoing therapeutic hypothermia for hypoxic-ischemic encephalopathy will be enrolled in a new protocol that will allow mothers to hold their infants during the hypothermia treatment period.
- Trial name
- NCT03079284
- Testing
- Holding during cooling
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Alexa Craig
Early Manifest Huntington Disease
A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease
This is the first study of branaplam in adults with Huntington's Disease (HD) to determine the correct dose required to lower mutant huntingtin protein (mHTT) levels in the cerebrospinal fluid (CSF) to a degree expected to be…
- Trial name
- VIBRANT-HD (NCT05111249)
- Testing
- Branaplam
- Where
- 12 sites in Canada, France and 3 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Polymyositis, Dermatomyositis
A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis
This was a Phase 2 randomized, double-blind, placebo-controlled, crossover, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of treatment with KZR-616 in patients…
- Trial name
- PRESIDIO (NCT04033926)
- Testing
- KZR-616
- Where
- 14 sites in United States, Czechia and 1 more
- Volunteers
- 25 people
- Sponsor
- Kezar Life Sciences, Inc.
Alzheimer Disease
Detecting an Early Response to Donepezil With Measures of Visual Attention
Acetylcholinesterase inhibitors (AChE-I) comprise a class of drugs used to treat Alzheimer's disease (AD), but controversy about their usefulness remains.
- Trial name
- NCT03073876
- Testing
- Donepezil Hydrochloride
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- NYU Langone Health
Epilepsies, Partial
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo
Patients with partial seizures currently taking 1-3 antiepileptic medications will have a 50:50 chance to receive Lyrica 300 mg per day or placebo (no active ingredients) added on to their current medications for 3 months.
- Trial name
- NCT00351611
- Testing
- Lyrica (pregabalin)
- Where
- 150 sites in United States, Bulgaria and 7 more
- Volunteers
- 187 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Chronic Troublesome Sialorrhea, Cerebral Palsy
Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
The objective of this study is to investigate the efficacy and safety of NT 201 compared with placebo for the treatment of chronic troublesome sialorrhea associated with neurological disorders (e.g.
- Conditions
- Chronic Troublesome Sialorrhea, Cerebral Palsy, Stroke, Traumatic Brain Injury
- Trial name
- SIPEXI (NCT02270736)
- Testing
- NT 201
- Where
- 31 sites in Georgia, Hungary and 4 more
- Volunteers
- 256 people
- Sponsor
- Merz Pharmaceuticals GmbH
Amblyopia
Study of Binocular Computer Activities for Treatment of Amblyopia
The purpose of the study is to compare the effectiveness of 1 hour/day of binocular game play 7 days per week with 2 hours/day patching 7 days per week in children 5 to <17
- Trial name
- ATS18 (NCT02200211)
- Testing
- iPad®, Patching 2 hours per day, 7 days per week
- Where
- 2 sites in United States
- Volunteers
- 485 people
- Sponsor
- Jaeb Center for Health Research
Post-Concussion Syndrome
The Effectiveness of Biofeedback for Individuals With Long-term Post-concussive Symptoms
Most concussions resolve within 7-10 days, but approximately 40% of individuals do not fully recover and suffer from persistent post-concussive symptoms.
- Trial name
- NCT03338036
- Testing
- Heart Rate Variability Biofeedback, Neurofeedback
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Western University, Canada
Parkinson Disease
Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease
To investigate the efficacy and the safety of ropinirole PR/XR tablets to ropinirole immediate release (IR) tablets with advanced Parkinson's disease in conjunction with L-dopa in a double-blind, parallel group comparison study.
- Trial name
- NCT00823836
- Testing
- ropinirole PR/XR, ropinirole IR
- Where
- 54 sites in Japan
- Volunteers
- 302 people
- Sponsor
- GlaxoSmithKline
Parkinson Disease, Parkinson's Disease
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
To evaluate the safety profile of ropinirole XL during long-term treatment in subjects with early and advanced Parkinson's disease
- Trial name
- NCT00632736
- Testing
- Ropinirole XL (formerly CR)
- Where
- 75 sites in United States, Belgium and 7 more
- Volunteers
- 419 people
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo
Alzheimer's disease (AD) is a fatal degenerative disease of the brain for which there is no cure. AD causes brain cells to die. AD is thought to be caused by an excess of beta amyloid (β-amyloid), a sticky protein in the brain…
- Trial name
- IDENTITY-2 (NCT00762411)
- Testing
- LY450139
- Where
- 91 sites in United States, Brazil and 16 more
- Volunteers
- 1,111 people
- Sponsor
- Eli Lilly and Company
Neuropathic Pain
Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.
This study will measure the impact of treatment with pregabalin in adult men and women who have a diagnosis of peripheral neuropathic pain (pain caused by a primary lesion of the peripheral nervous system such as Diabetic…
- Trial name
- NCT00219544
- Testing
- Pregabalin (Lyrica)
- Where
- 30 sites in Canada
- Volunteers
- 158 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.